NHS England is stumping up £190m to pay for new hepatitis C treatments from AbbVie and Gilead that are yet to receive full funding from the country's health service.
The NHS's main commissioning body said that the existing budget for these drugs would be increased to £190m - up from the £40m budget that began last year.
This is the NHS's single largest investment in new treatments this year (except for the £280m Cancer Drugs Fund), but comes after a long delay for this extra funding stream.
The money will go to the roughly 3,500 hepatitis C patients in England and Wales with cirrhosis of the liver, and will gain access by the end of this year to AbbVie's Viekirax, a three-drug combination therapy for the disease, and Exviera (dasabuvir), as well as Gilead's hep C pills Sovaldi and Harvoni.
Labels: access to drugs, NHS, UK